Alzheimer's disease (AD) is the most frequent cause of dementia and cholinesterase inhibitors are the available treatment in the mild stage. However cognitive rehabilitation has shown satisfactory results when combined with pharmacological treatment. Behavioral alteration is common in AD patients, which burdens caregivers and raises the risk of institutionalization. Providing caregivers guidance may enable them to assure better quality of life for patient and caregiver and lower institutionalization rates. OBJECTIVE: To evaluate the effects of a neuropsychological rehabilitation program (NRP) combined with pharmacological treatment in early stage AD patients. METHODS: We studied 12 AD patients (6 women), average age 75.42 (6.22) with 9.58 (5.6) years education in use of stable doses of cholinesterase inhibitors. Cognitive performance was evaluated using Mini-Mental State Examination (MMSE) and Alzheimer´s Disease Assessment Scale-cognitive (ADAS-Cog). Caregivers responded to Neuropsychiatric Inventory (NPI) and Functional Activities Questionnaire (FAQ) at initial evaluation (T1), and after 8 months of rehabilitation program (T2). The program comprised two sessions every week and family guidance every fortnight. RESULTS: MMSE (T1:23.25 (1.82)/T2:23.42 (2.81); ADAS-Cog (T1:17.11 (6.73)/T2:21.2 (8.59); NPI (T1:23.42 (23.38)/T2:19.83 (17.73); FAQ (T1:10.67 (7.24)/T2: 13.92 (6.92). CONCLUSIONS: These results show the importance of providing guidance and support for caretakers. Study limitations were the small number of patients and absence of a control group with only drug treatment to compare with combined pharmacological and rehabilitation treatments.
Alzheimer's disease (AD) is the most frequent cause of dementia and cholinesterase inhibitors are the available treatment in the mild stage. However cognitive rehabilitation has shown satisfactory results when combined with pharmacological treatment. Behavioral alteration is common in AD patients, which burdens caregivers and raises the risk of institutionalization. Providing caregivers guidance may enable them to assure better quality of life for patient and caregiver and lower institutionalization rates. OBJECTIVE: To evaluate the effects of a neuropsychological rehabilitation program (NRP) combined with pharmacological treatment in early stage AD patients. METHODS: We studied 12 AD patients (6 women), average age 75.42 (6.22) with 9.58 (5.6) years education in use of stable doses of cholinesterase inhibitors. Cognitive performance was evaluated using Mini-Mental State Examination (MMSE) and Alzheimer´s Disease Assessment Scale-cognitive (ADAS-Cog). Caregivers responded to Neuropsychiatric Inventory (NPI) and Functional Activities Questionnaire (FAQ) at initial evaluation (T1), and after 8 months of rehabilitation program (T2). The program comprised two sessions every week and family guidance every fortnight. RESULTS: MMSE (T1:23.25 (1.82)/T2:23.42 (2.81); ADAS-Cog (T1:17.11 (6.73)/T2:21.2 (8.59); NPI (T1:23.42 (23.38)/T2:19.83 (17.73); FAQ (T1:10.67 (7.24)/T2: 13.92 (6.92). CONCLUSIONS: These results show the importance of providing guidance and support for caretakers. Study limitations were the small number of patients and absence of a control group with only drug treatment to compare with combined pharmacological and rehabilitation treatments.
The numbers of families affected by dementia has risen drastically in recent decades.
Care-giver guidance may lead to improved quality of life for both and less patient time
in hospital, mainly by reducing behavioral disturbances. The publication “Guidelines for
managing Alzheimer’s Disease”,[1]
suggests that a treatment plan should be developed when the diagnosis has been made.
This plan should include: pharmacological therapy (with cholinesterase inhibitor to
temporarily improve cognition or slow the rate of cognitive decline), managing possible
co-morbidity, treatment of behavioral symptoms and mood disorders and finally support
for patients and their relatives.In addition, following recommendations and suggestions of the Cognitive Neurology and
Aging Department of the Brazilian Academy of Neurology,[2] cognitive rehabilitation may be indicated as
supplementary treatment (combined with medicamentous therapy) in patients with mild to
moderate DA since two studies published in Brazil[3-4] have demonstrated its
positive effects.Had previously noted that neuropsychological rehabilitation should not only work for
cognitive improvement but also seek to enable patient and family to deal with everyday
life, and work around, reduce or overcome cognitive, emotional and social impairments to
obtain significant improvement in quality of life.[5]Behavioral disturbances are very frequent in AD and may take place from the initial
phases. Their frequency varies across studies, but in the initial phases the most
frequently reported symptoms are: apathy (70%), anxiety[6] (48%), depression (50%) and irritability
(42%).[7] According to psychotic
behavior is more frequent in the moderate to severe stages.[6] These disorders are associated with higher probability
of institutionalization and increased numbers of medications used by these patients.
Another fundamental aspect is the subjective burden for caregivers when patients have
behavioral disorders.
Objectives
Verify the effect of a family guidance program by administering questionnaires
containing and functional and behavioral scales to caregivers of mild AD patients.
Note that the measure of success of a rehabilitation strategy is evaluated in daily
life rather than in the therapeutic environment since the aim is to have patients
become more adapted and functional in their own surroundings.
Methods
Patients
Subjects were 12 patients (six women) average age 75.42 (6.22) and 9.58 (5.60)
years schooling diagnosed as probable AD using the NINCDS-ADRDA
criteria[4] and AD
diagnosis using DSM-IV criteria 5. Subjects were recruited at the UNIFESP/ EPM
hospital complex (Hospital São Paulo and Hospital Santa Marcelina).
Patients were first subjected to medical testing to confirm clinical diagnosis
and indicate the stage of the disease, and to detect possible co-morbidities
that might affect the research. Another inclusion criterion was having a
family-member caregiver. The composition of the latter group in terms of family
relations was as follows: spouses n=7, children n=3, sister n=1 and
daughter-in-law n=1.Family-member caregivers were informed of the research goal and procedure and
provided signed consent for patient’s participation in the study, promised to
take part in the orientation program, and were told that after three consecutive
absences the patient and family-member caregiver would be removed from the
study.All underwent neurological and neuropsychological evaluation before and after
eight months intervention and were taking stable doses of cholinesterase
inhibitors.The following steps were taken to control the variations common to
clinical studies:(a) tests were administered in semi-random order, in other words, the
neuropsychological evaluation procedure was divided into four
blocks, maintaining a fixed order of tests within each block. Only
the first block contained tracking tests and batteries. The other
three blocks were administered in random order;(b) test instructions were standardized and read by the examiner;c) evaluation conditions were virtually to the same for all subjects
(physical space, lighting, testing materials, and others);d) examiners were trained to administer the tests prior to
administering them.
Cognitive and functional evaluation
Tests were conducted before and after a family guidance program:Mini-Mental State Examination[8-9] –
maximum score 30 points;ADAS-Cog [10-11]– maximum 70
points;Bayer Daily Life Activity Scale (B-AVD)[12] - consisting of 25 questions to
evaluate the degree of patient difficulty when performing tasks,
measured on a scale from 1 (no difficulty) to 10 (cannot do);Functional Activities Questionnaire (FAQ):[13] questionnaire that evaluates
functional activities with maximum score 30 points.
Behavioral evaluation
Neuropsychiatric Inventory[14] which evaluates behavioral and
psychological disturbances, such as delusions, hallucinations,
agitation, dysphoria, anxiety, apathy, irritability, euphoria,
disinhibition, aberrant motor behavior, night-time behavior
disturbances, and delirious ideas (measures frequency and severity
of each disturbance);The Revised Memory and Behavior Problems Checklist -[15] this scale
appraises the frequency of patient behavior problems and the
reaction they provoke in caregivers The higher the score, the more
frequent the behavioral problems and the worse the caregiver’s
reaction to these problems.Functional and behavioral evaluations were conducted using scales that caregivers
responded to in groups. Presentation was through a projector and the study was
conducted with advice from three professionals (two neuropsychologists and an
occupational therapist), for two hours duration.
Family guidance program (FG)
The eight-month program involved a fortnightly session lasting an hour and a
half. The study was developed at the São Paulo Neuropsycology Center,
Universidade Federal de São Paulo (UNIFESP).FG consisted of:Information about AD in the form of a talk, referring mainly to
cognitive and behavioral evolution and disturbances. It also covered
available medication treatment;Guidance for relatives on how to approach and cope with cognitive and
behavioral disturbances;Restructuring routines with relatives and implementing functional
strategies. External supports were used (calendar, pages with
personal data and diary), plus advice on how to improve
communication with patients;Dietary guidelines;Family therapist guidance at the end of the period, comprising two
sessions dealing with emotional issues raised by family caregivers
in an attempt to join the interests of patients and caregivers.
Statistical analysis
A significance level of 5% (0.050) was adopted for use of statistical tests in
this study. The program used in analyses was the Statistical Package for Social
Science” (SPSS).Descriptive analyses were made for continuous category data (average, standard
deviation, minimum and maximum). Pre- and post-treatment scores were compared
using the Wilcoxon test.The project was approved by the Research Ethics Committee, Universidade Federal
de São Paulo. Informed consent forms were signed by the main caregivers
and/or legal guardians.
Results
Table 1 shows demographics. On comparing the
first and last evaluations, we noted a relative stabilization of results (after 8
months of intervention) as shown in Table
2.
Table 1
Demographic characteristics.
Mean
Standard deviation
Minimum value
Maximum value
Gender (n)
F (6) / M (6)
-
-
-
Age
75.42
75.42
64
84
Educational level
9.58
5.60
4
15
F: female; M: male.
Table 2
Comparisons between first and second scores on cognitive, behavior, and
functional evaluations.
Mean (first evaluation)
SD
Mean (second evaluation)
SD
Z
p value
MEEM
23.25
1.82
23.42
2.81
-0.197
0.844
ADAS-Cog
17.11
6.73
21.20
8.59
-1.255
0.209
Pfeffer
10.67
7.24
13.92
6.92
-1.735
0.083
NPI
23.42
23.38
19.83
17.73
-1.138
0.255
Bayer
101
45.27
107
53.33
-0.628
0.530
Wilcoxon test.
Demographic characteristics.F: female; M: male.Comparisons between first and second scores on cognitive, behavior, and
functional evaluations.Wilcoxon test.
Discussion
Our research findings corroborate those in the literature on behavior alteration in
early-stage AD patients and suggest that non-pharmacological treatment may delay
onset of behavioral and mood disturbances and enhance quality of life for these
patients and their caregivers and consequently reduce institutionalization[16-18]. However it is important to note that patients in this
study were submitted to individual and group intervention (once a week for each
type) which may explain the stable cognitive, functional and behavioral scores from
first to second evaluation. However note that The Revised Memory and Behavior
Problems Checklist,[15] which
evaluates caregiver response to memory, behavior and humor alterations, also found
an improvement in caregiver response to alterations presented by patients (Memory-
Z= –0.314 And P=0.753; Behavior Z= –1.309 and p=0.474; Mood Z= –1.309 and p=0.191).
These findings are compatible with those of Abrisqueta-Gomez et al.[3]Note that behavioral alterations are directly related to worsening of patient
functionality.[19,20] Another extremely important point
is the patient environment, which calls for a restructuring routine with
implementation of functional strategies able to make patients more functional and
better adapted patient to this environment. However we find this often meets with
initial resistance from patients still in the early stage whose critical faculties
and judgment are relatively intact. Therefore our guidance sessions included
explanation and training on this point since caregivers also would their routines
restructured. On this issue, we conducted a caregiver evaluation four months into
the study, but the findings have yet to be analyzed.Some studies also point that behavior alteration in patients may be associated with
caregiver stress, depression and anxiety.[21-23]. On analyzing
findings using The Revised Memory and Behavior Problems Checklist[15], which evaluates caregiver
responses to memory, behavior and mood alterations, we found improved caregiver
response to alterations presented by patients (Memory- Z= –0.314 and p=0.753;
Behavior Z= –1.309 and p=0.474; Mood Z= –1.309 and p=0.191). This finding matches
those of Abrisqueta-Gomez et al.[3]
An important point is that patients present less behavioral alteration in the early
stages.After systematically reviewing studies on information and support for dementia
patients’ caregivers, concluded that this was a significantly positive effect in
relation to caregiver depression.[24] Previous studies conducted at SARI showed the importance of
evaluating these aspects before starting a rehabilitation program.[3] Published a study of family
caregivers in which A-B-C behavior modification technique was used (A–activator,
B–behavior observed and C–consequence).[21-25] In this study,
the caregiver was taught to identify alteration triggering situations and then
trained to monitor patient’s daily behavior and make notes when the target behavior
occurred, identifying situations or whatever was associated with this occurrence.
Caregivers were then taught behavioral change strategy. In our own study this
technique was not used in full but our guidance sessions for caregivers did include
behaviors that might elicit alterations in patients. We also talked about how to
improve communication, another factor that may lead to patient behavior alterations
since there is often decline in language, mostly in naming.[26] Guidance included behavioral tips
for caregivers such as “always look at the patient when talking to them, use short
and simple sentences.”In light of our findings, we may conclude that there is evidence of the importance of
work developed with caregivers and or family to ensure guidance and support: being
informed of the course of the disease, identifying their own behavior that may
elicit behavior alteration, sharing caring work with others without feeling
guilty.Given these results we may conclude that there is evidence of the importance of the
work developed with caregivers and/or relatives to provide advice and support. There
may be limitations for the results due to the reduced number of patients; however
group numbers in studies in the literature are also low, due to the difficulty of
the rehabilitation process. An obstacle is the major difference among the study
designs of intervention in degenerative disease patients. A limitation for this
study was the absence of a group control that would allow us to compare the combined
treatment effect (neuropsychological rehabilitation + cholinesterase inhibitor) with
the effect of medication alone. It is important to point out that the measure of
success of a rehabilitation strategy is evaluated in daily life rather than in the
therapeutic environment, since the aim of this work is to make patients more
functional and adapted to their environment.
Authors: Sonia M D Brucki; Ricardo Nitrini; Paulo Caramelli; Paulo H F Bertolucci; Ivan H Okamoto Journal: Arq Neuropsiquiatr Date: 2003-10-28 Impact factor: 1.420
Authors: Jacqueline Abrisqueta-Gomez; Fabiola Canali; Vera L D Vieira; Ana Cristina P Aguiar; Carmen S C Ponce; Sonia M Brucki; Orlando F A Bueno Journal: Arq Neuropsiquiatr Date: 2004-10-05 Impact factor: 1.420